Major Shareholder Atlas Venture Discloses $23.57M in Recent Stock Sales
DYN has more than doubled off its 52-week low of $8.06.
Summary
Atlas Venture, a major institutional investor, has disclosed selling approximately $23.57 million worth of Dyne Therapeutics common stock over the past week, signaling a significant reduction in its holdings.
Key Events · Ownership and Investor Activity · DYN
-
Significant Shareholder Selling
Atlas Venture entities sold approximately $23.57 million worth of common stock between April 20 and April 27, 2026.
-
Institutional Distribution
The sales represent a notable reduction in holdings by a major institutional investor, contributing to an ongoing distribution pattern observed among insiders.
Analysis · DYN · Life Sciences
Atlas Venture, a significant institutional shareholder, has reported substantial sales of Dyne Therapeutics common stock totaling approximately $23.57 million between April 20 and April 27, 2026. This ongoing distribution by a major investor, representing nearly 0.8% of the company's market capitalization, indicates a reduction in their stake. This selling activity occurred around the same time as the company announced positive preclinical data, suggesting the sales are part of a pre-planned or continuous liquidation strategy rather than a direct reaction to recent news.
How filings like this one have moved
In the 30 days to Sep 16, 2026, 30% of the 1759 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.34%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, DYN was trading at $18.16 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $3B. The 52-week trading range was $8.06 to $25.00. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.